Date: 2015-09-01
Type of information: Nomination
Compound:
Company: Erytech Pharma (France)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 1, 2015, Erytech Pharma, the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announced the appointment of Eric Soyer as Chief Financial and Chief Operating Officer (CFO/COO). Mr. Soyer brings more than 20 years of experience in executive leadership positions with responsibility for financial and operational functions with established and emerging public and private companies. Over the past eight years Eric served as the Group CFO of the Lyon based, NASDAQ listed therapeutic ultrasound
company EDAP-TMS, where he was responsible for finance, administration, investor relations, legal affairs, and human resources. During the past three years at EDAP-TMS, he was also Managing Director of the French affiliate of the group with responsibility for R&D and manufacturing operations and distribution for France, South America and EMEA.
Previously, he was the CFO and Chief Information Officer for a French leader in nursing homes and postacute care clinics, and CFO and Legal Director for a leading French insurance company. He started his career as International Financial Controller at the Michelin Group.
Mr. Soyer received his Executive M.B.A. from HEC Paris, his M.B.A. from the University of Kansas in the United States and graduated from ESC Clermont School of Management in France.
Financial terms:
Latest news:
